28.78
-0.94 (-3.16%)
| Penutupan Terdahulu | 29.72 |
| Buka | 29.20 |
| Jumlah Dagangan | 5,616,037 |
| Purata Dagangan (3B) | 7,135,921 |
| Modal Pasaran | 20,597,878,784 |
| Harga / Jualan (P/S) | 1.48 |
| Harga / Buku (P/B) | 4.79 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Feb 2026 |
| Margin Operasi (TTM) | -4,823.84% |
| EPS Cair (TTM) | -0.750 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -16.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -96.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.93% |
| Nisbah Semasa (MRQ) | 33.47 |
| Aliran Tunai Operasi (OCF TTM) | -839.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -375.20 M |
| Pulangan Atas Aset (ROA TTM) | -10.73% |
| Pulangan Atas Ekuiti (ROE TTM) | -12.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Roivant Sciences Ltd. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.63 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 30.31% |
| % Dimiliki oleh Institusi | 83.49% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Qvt Financial Lp | 31 Dec 2025 | 26,387,021 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 35.00 (Citigroup, 21.61%) | Beli |
| Median | 33.00 (14.66%) | |
| Rendah | 30.00 (Guggenheim, 4.24%) | Beli |
| Purata | 32.80 (13.97%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 25.67 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 34.00 (18.14%) | Beli | 29.52 |
| 10 Feb 2026 | 33.00 (14.66%) | Beli | 27.35 | |
| Citigroup | 10 Feb 2026 | 35.00 (21.61%) | Beli | 27.35 |
| Guggenheim | 09 Feb 2026 | 30.00 (4.24%) | Beli | 27.67 |
| Goldman Sachs | 15 Dec 2025 | 33.00 (14.66%) | Beli | 21.90 |
| Leerink Partners | 15 Dec 2025 | 32.00 (11.19%) | Beli | 21.90 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |